Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

HIV Infections Clinical Trial

Official title:

Randomised, Double Blind, Placebo-controlled Dose Ranging Trial to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02232581
• Other study ID #: 1211.1
• Status: Completed
• Phase: Phase 2
• First received: September 4, 2014
• Last updated: September 4, 2014
• Start date: April 2004

Study information

• Verified date: August 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
• Study type: Interventional

Clinical Trial Summary

The primary objective was to determine the mean change in HIV viral load from baseline to Week 4 compared with placebo after 4 weeks of treatment in highly experienced HIV-infected patients.

Secondary objectives were to determine (1) the tolerability, hematologic and hepatic safety of different doses of alovudine and (2) the effect of baseline nucleoside genotypic susceptibility on virologic response after 4 weeks of alovudine administration

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. primary completion date: December 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent before any trial procedure

• HIV-1 infected males or females =18 years of age

• Screening genotypic resistance report indicating two or more of the following nucleoside reverse transcriptase inhibitors (NRTI) resistance mutations: 41, 67, 70, 210 and 215

• Stable NRTI regimen without stavudine and zidovudine for at least 6 weeks before screening and stable antiretroviral (ARV) background treatment for 3 months before screening

• HIV-1 viral load =1000 copies/mL and <75,000 copies/mL at screening

• Change in viral load between previous test within 3 months before screening, using local laboratory for routine tests, and screening test was <1.0 log10 copies/mL

• Acceptable medical history, as assessed by the investigator

• Current stable ARV medication regimen between screening (Visit 1) and Visit 2

Exclusion Criteria:

• ARV medication naïve

• Patients on recent drug holiday, defined as off ARV medications for at least 7 consecutive days within the previous 3 months

• Female patients of child-bearing potential who :

• have a positive serum pregnancy test

• are breast feeding,

• are planning to become pregnant, or

• are not willing to use a barrier method of contraception

• Prior alovudine use

• Use of investigational medications within 30 days before study entry or during the trial

• Use of immunomodulatory drugs within 3 months before study entry or during the trial (e.g. interferon, cyclosporine, hydroxyurea, interleukin-2)

• Current use of rifampin, rifabutine, isoniazid, pyrazinamide, stavudine, zidovudine, ganciclovir, chronic use of hepatotoxic drugs, anti-tumour therapy or probenecid

• Laboratory values:

• Neutrophils of Grade 2 or greater abnormality

• Hemoglobin of Grade 2 or greater abnormality

• Platelets: Grade 2 or greater abnormality

• Creatinine of =1.25 Upper limit of the normal (ULN)

• Lipase of Grade 1 or greater abnormality

• Alanine aminotransaminase (ALT) or Aspartate aminotransaminase (AST) of Grade 2 or greater abnormality

• Direct bilirubin of Grade 1 or greater abnormality

• CD4 =50 cells/mm3

• Hepatitis B (+HBsAg or +HBcAB) or C +Hepatitis C virus (+HCV AB ) co-infection, chronic hepatitis, on-going hepatitis or pancreatitis

• Any new or active AIDS-defining event within 30 days before study entry

• Inability to adhere to the requirements of the protocol, including active substance abuse as assessed by the investigator

• In the opinion of the investigator, likely survival of less than 6 months because of underlying disease

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Alovudine - low

• Alovudine - medium

• Alovudine - high

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in HIV viral load measured from plasma samples		Up to 4 weeks after drug administration	No
Secondary	Percentage of virologic responders per treatment arm		Up to 4 weeks after drug administration	No
Secondary	Proportion of patients experiencing a change of viral load	viral load of =1 log10 from baseline to Week 4	Up to 4 weeks after drug administration	No
Secondary	Mean change in CD4+ cell count		Up to 4 weeks after drug administration	No
Secondary	Percentage of 0.5 virologic responders per treatment arm		Up to 4 weeks after drug administration	No
Secondary	Percentage of load responders per treatment arm		Up to 4 weeks after drug administration	No
Secondary	Percentage of 0.7 to 0.9 virologic responders per treatment arm		Up to 4 weeks after drug administration	No
Secondary	Number of patients with adverse events		Up to 4 weeks after drug administration	No
Secondary	Number of patients with laboratory test abnormalities and with respect to Division of AIDS (DAIDS) grading		Up to 4 weeks after drug administration	No
Secondary	Number of patients with serious adverse events		Up to 4 weeks after drug administration	No
Secondary	Number of patients who discontinued due to adverse event		Up to 4 weeks after drug administration	No
Secondary	Mean change in CD8+ cell count		Up to 4 weeks after drug administration	No
Secondary	Number of patients with abnormal changes in laboratory parameters		Up to 4 weeks after drug administration	No

External Links

•   Link